biostudies-literatureWang DSGuangdong Basic and Applied Basic Research FoundationNational Natural Science Foundation of Chinae1004389https://www.ebi.ac.uk/biostudies/studies/S-EPMC11086847biostudies-literatureUnknown21(5)<h4>Background</h4>It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM.<h4>Methods and findings</h4>This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked rPLoS medicineCetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.PMC11086847820733022023B1515020015Chen JQQiu MZWang FLiu TSFong WPZhang RPan ZZXie DJWan DSXu RHWang ZQDing PRLi SSWang FHWang XZLuo HYChen TYuan YYuan YFLu ZHZheng YChen GWu XJWang LYWang DSRen CLi YHLi BKZhai XHXiao JLi LRTan QfalseCetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.<h4>Background</h4>It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM.<h4>Methods and findings</h4>This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked r2024-01-01T00:00:00Z2024 May2026-06-03T01:32:17.073Z2026-04-22T03:13:20.079ZS-EPMC110868473872836410.1371/journal.pmed.1004389